Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at [email protected].
This month’s biosimilars month in review highlights the evolving landscape of biosimilars, emphasizing their potential benefits in terms of safety, cost-effectiveness, and increased treatment options, while recognizing the importance of addressing challenges in adoption and perception.
The approval was based on clinical data from 3 multicenter, randomized trials which demonstrated the safety, efficacy, and biosimilarity of adalimumab-ryvk compared with the reference product.
Of those who received an infliximab biosimilar, 87.8% were maintained on a single biosimilar without the need to switch to an alternative product.
Clinical equivalence was demonstrated for the primary and key secondary endpoints between patients receiving MSB11456 and its reference drug, tocilizumab.
The biosimilars month in review explores the efficacy and safety of biosimilars in treating uveitis, highlights the FDA’s acceptance of a biologics license application for an ustekinumab biosimilar, and emphasizes the safety and accessibility benefits of biosimilars in rheumatic conditions.
VX-548 demonstrated a more rapid onset to meaningful pain relief post-surgery compared with placebo.
On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.
A significantly larger proportion of patients receiving the biosimilar QL0911 achieved a durable platelet response when compared with placebo.
Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.
The FDA has extended the shelf-life of 4 mg naloxone hydrochloride nasal spray (Narcan) for nonprescription over-the-counter use from 3 years to 4 years.
During a 10-year period, estimated access to drugs increased among Polish patients with rheumatic and musculoskeletal diseases.
Investigators evaluated employment rates at various disease stages of rheumatoid arthritis (RA) to uncover the key predictors influencing work among this patient population. Test your knowledge of employment and RA with this quiz.
The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.
Efficacy, pharmacokinetics, immunogenicity, and safety were comparable between patients receiving the aflibercept biosimilar SB15 and the reference drug.
Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 diabetes.
Despite a boom of new, cost-efficient options for chronic conditions, prescriber and patient concern over clinical benefit persists.
Thyroid dysfunction was greater among patients with more severe CKD coupled with a high urine protein level.
Patients who reported almost daily fresh vegetable consumption had higher eGFR compared to those with occasional consumption and those who consumed salt-preserved vegetables.
A higher prevalence of STI diagnosis is observed in adolescents and young adults with sickle cell disease compared with controls.
Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.
The revised algorithm demonstrates 97% sensitivity in identifying pregnant patients with inherited bleeding disorders.
Peter C Taylor, PhD, discusses the current treatment landscape in rheumatoid arthritis and the unmet needs of this patient population.
The decision was based on both clinical and non-clinical data supporting the biosimilarity of bevacizumab-tnjn (Avzivi), previously named BAT1706.
Significant increases in macular and choroidal thickness were observed in the fovea and perifovea at all postoperative visits in patients with diabetic retinopathy.
In an interview with HCPLive, Juliana Reed, MS, explains the pivotal role biosimilars play in healthcare and the barriers to access and adoption.
The biosimilars month in review highlights top data demonstrating the efficacy of biosimilars for treating inflammatory bowel disease and plaque psoriasis, as well as trends in adopting biosimilars among patients and clinicians in the US.
Russell D Cohen, MD, explains how biosimilars represent an opportunity to expand access and reduce the financial burden of high-cost biologics.
The PEAUrigami art exhibit was designed to educate participants to better understand the pathophysiology of skin using origami artwork with skin pattern-printed papers.
Therapy with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at posttreatment week 12 rate, which was superior to the prior efficacy threshold.
sLOX-1 was positively associated with high-risk coronary plaque features in patients with psoriasis and increased inflammation.
